The strategy is a sign of Teva’s commitment to its $40 billion bid for Mylan, as the latter presses on with its own $34 billion hostile bid for over-the-counter drug company Perrigo Company Plc (PRGO.N). Teva last week disclosed a 1.8 percent stake in Mylan, which blasted the move as breaching U.S. antitrust laws because of the stake’s size. Teva’s stake in Mylan far exceeds that threshold.